Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.63 USD
-0.08 (-0.19%)
Updated May 1, 2024 04:00 PM ET
After-Market: $42.61 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CERE 42.63 -0.08(-0.19%)
Will CERE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CERE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CERE
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Other News for CERE
Polaris Global Equity Composite Q1 2024 Commentary
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug